10076445Developing first-in-class aggregation-specific antibodies for a severe genetic neurological diseaseClosedGrant for R&DInnovate UKGOM Therapeutics is developing a first-in-class therapeutic for a common genetic neurovascular disease with no existing treatment. The disease is a progressive, chronic adult-onset disorder that leads to dementia, physical disability and premature death. This heritable condition significantly affects the lives of patients and their families. We are taking a highly innovative approach, building on important recent scientific advances. Our project aims to assess the feasibility of making an important starting component for our drug discovery process. This project represents an important step in potentially bringing a novel therapy to an underserved group of patients.